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Abstract
The pathology of Alzheimer’s disease (AD) is characterized by the presence of extracellular deposits of misfolded and
aggregated amyloid-b (Ab) peptide and intraneuronal accumulation of tangles comprised of hyperphosphorylated Tau
protein. For several years, the natural compound curcumin has been proposed to be a candidate for enhanced clearance of
toxic Ab amyloid. In this study we have studied the potency of feeding curcumin as a drug candidate to alleviate Ab toxicity
in transgenic Drosophila. The longevity as well as the locomotor activity of five different AD model genotypes, measured
relative to a control line, showed up to 75% improved lifespan and activity for curcumin fed flies. In contrast to the majority
of studies of curcumin effects on amyloid we did not observe any decrease in the amount of Ab deposition following
curcumin treatment. Conformation-dependent spectra from p-FTAA, a luminescent conjugated oligothiophene bound to
Ab deposits in different Drosophila genotypes over time, indicated accelerated pre-fibrillar to fibril conversion of Ab1–42 in
curcumin treated flies. This finding was supported by in vitro fibrillation assays of recombinant Ab1–42. Our study shows that
curcumin promotes amyloid fibril conversion by reducing the pre-fibrillar/oligomeric species of Ab, resulting in a reduced
neurotoxicity in Drosophila.
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Introduction
Drosophila melanogaster (Drosophila) has during the past decade
emerged as a promising model system for Alzheimer’s disease (AD)
research [1,2,3]. Expression of various AD-related human proteins
e.g., amyloid-b (Ab) and Tau, in the Drosophila model system
results in animals displaying many of the histological hallmarks of
AD seen in humans [4], as well as a correlation of lifespan to
aggregation propensity of the protein or peptide expressed [5]
which surpasses that of corresponding rodent models. Drosophila
Ab models have also been used as platforms for pharmacological
treatment assays by the putative aggregation inhibitor Congo red
[3], designed native state stabilizers [6], and by genetic mani-
pulations co-expressing molecular chaperones [7].
For several years, curcumin has been proposed to be a
candidate drug for enhanced clearance of the toxic amyloids
generated by the Ab peptide. Curcumin has also been reported to
have anti-inflammatory and anti-oxidative activity thus preventing
tissue damage [8,9,10,11], to reduce Ab-induced toxicity [12], as
well as to reduce microglia activation [13]. Many studies, in vitro
and in vivo, have shown inhibition of Ab oligomer [9] and fibril
formation [9,14,15,16] in the presence of curcumin, depending on
the used assay. Curcumin appears to be a promiscuous AD-drug
as it has also been shown to block Ab toxicity in vivo through
inhibition of Tau phosphorylation [11,17], as well as regulating
AbPP and BACE-1 transcription by interfering with copper ions
[18] in cell cultures. Because of these promising results curcumin
has been tested in humans as a drug candidate for AD [19]. The
dominating view is that curcumin is an aggregation inhibitor, but
recent studies of curcumin have shown that while it inhibits the
oligomeric forms of Ab, it accelerates the formation of Ab fibrils
[20]. Curcumin is a potent binder of amyloid deposits, making it
a molecular candidate for histological staining in pathology
[9,21,22], and it has been suggested as a useful derivate in
combination with near-infrared imaging in living subjects [23]. In
addition to these results, curcumin has also shown effects, mainly
due to its anti-inflammatory properties, on other diseases such as
rheumatoid arthritis, pancreatitis, cancer, osteoarthritis, and in
some ocular as well as gastrointestinal conditions, such as
ulcerative colitis [24]. Current drug development strategies include
development of curcumin analogues with similar biological activity
as curcumin, but with improved pharmacokinetic characteristics,
including increased bioavailability and water solubility [25].
Amyloidogenic proteins are known to be able to assemble into
multiple forms of amyloid-like structures in vitro in a process known
as ‘‘amyloid fibril polymorphism’’ [26,27] suggesting that several
mechanisms may be involved in amyloid formation. Multiple
fibrillation pathways will probably result in multiple forms of pre-
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these complex folding processes and curcumin is not clear.
Here, we have addressed the potency of curcumin in alleviating
AD-like symptoms in transgenic Drosophila models of AD. To this
end we used four different Ab expressing Drosophila lines (Ab1–40
single transgene, Ab1–42 single transgene, Ab1–42 double transgene,
and Ab1–42 E22G single transgene) [3], and one human Tau
expressing Drosophila line [1], all expressed in the Drosophila central
nervous system (CNS) and eyes by the Gal4/UAS system [28].
The longevity and the locomotor activity of the different genotypes
were measured relative to a control line. To detect amyloid
formation ex vivo, we combined antibody staining with a lumi-
nescent conjugated oligothiophene, p-FTAA [29], as a marker for
amyloid, and collected structural dependent spectra from the
probe for different time points as the aggregation accelerates in the
tissue. These results, combined with in vitro fibrillation of
recombinant Ab and quantification of the soluble and insoluble
Ab produced in the flies in absence or presence of curcumin,
shows that curcumin does not inhibit amyloid formation. On the
contrary, curcumin rather accelerates amyloid fibril conversion,
and hence reduce the pre-fibrillary species of Ab. This suggests
that the reduction of pre-fibrillar species underlies the observed
mitigated neurotoxicity in Drosophila.
Results
Drosophila longevity
To address the effects of curcumin upon AD-related symptoms in
Drosophila, we initially fed various concentrations of curcumin (0–
0.01% w/w in yeast paste) to the control flies. Rather unexpectedly,
this however rendered a reduced lifespan. The reduced viability was
curcumin concentration dependent, resulting in a decreased median
survival time (T1/2)( F i g u r e1 A ) .T h eA b1–40 expressing flies showed a
decreased T1/2 compared to the control flies, and was only affected
by the higher curcumin concentrations, also here resulting in a
decreased life span. For the low concentration of curcumin, the
lifespan was unaffected (Figure 1B). Curcumin feeding of the single
inserted Ab1–42 expressing flies showed a positive effect of the T1/2 at
low and intermediate curcumin concentrations and no effect of the
T1/2 on the highest curcumin concentration (Figure 1C). Curcumin
feeding of the double inserted Ab1–42 expressing flies showed a
positive effect at low and intermediate concentrations of curcumin
treatments. The lifespan for high curcumin concentration treated flies
was not apparently different when compared to the untreated flies
(Figure 1D). All curcumin treatments of the Ab1–42 E22G expressing
flies showed a substantial positive effect upon curcumin treatment.
The greatest observed effect was found on 0.001% curcumin
treatment of the Ab1–42 E22G expressing flies, which increased the
T1/2 by 75% compared to untreated flies (Figure 1E). Curcumin
feeding of the Tau expressing flies rendered no effect on survival at
low concentrations, but a toxic effect on high concentrations of
curcumin (Figure 1F). The median survival time (Figure 1G) of all
transgenes and curcumin concentrations displayed a clear effect upon
curcumin treatment for genotypes having the strongest phenotype.
The toxic effect on curcumin treatment was balanced with the
rescuingeffectofgenotypeshavingamildphenotype.TheT1/2 for all
genotypes and curcumin concentrations are summarized inTableS1.
The results from the longevity assay were essentially mirrored in a
conventional climbing assay with a reduced climbing shifted of 1–2
days prior to death (Figure S1) as reported in previous studies [30].
Drosophila locomotor activity
The DAM2 system automatically counts the number of beam
breaks for flies walking in a horizontal tube over a period of
24 hours [31]. This setup allowed for characterization of the
locomotor and behavior rhythms of Drosophila. Comparing the
locomotor activity of the flies without curcumin treatment at day 5
(c.f. Figure 2A, E, I, M, Q, U), there were obvious differences in
the activity and circadian rhythm between the different genotypes.
The DAM2 system hence appeared more sensitive for assaying
early signs of neurological impairment compared to the conven-
tional climbing assay (cf. Figure 2 with Figure S1). Studies of
continuous curcumin treatment of flies at the intermediate
concentration (0.001%) was performed at different days of aging,
with 5 days increments. Control flies showed slight activity
deterioration upon curcumin treatment. Overall, the locomotor
activity of the flies decreased with increasing age, but the number
of beam breaks per hour was almost consistent during the first
hours of the assay. The decreased total number of beam brakes
upon increased age was caused by the shortened number of active
hours (Figure 2A–D). Ab1–40 expressing flies showed no activity
improvement upon curcumin treatment (Figure 2E–H). Single
insert Ab1–42 expressing flies showed a higher number of beam
breaks and a continuation of activity during a larger number of
hours upon curcumin treatment for flies at 5 and 10 days
(Figure 2I–L). The effect of curcumin showed a tendency of
decreasing with age (Figure 2L). Double insert Ab1–42 expressing
flies showed an activity enhancement upon curcumin treatment
for flies of all ages (Figure 2M–P). Also here the effect of curcumin
showed a tendency of declining with age (Figure 2P). The Ab1–42
E22G expressing flies showed a severely decreased locomotor
activity already at day 5 compared to control flies (c.f. Figure 2A
and 2Q). Curcumin treated Ab1–42 E22G expressing flies at day 5
showed an increased number of beam breaks per hour during the
first hours, but the number of active hours was not significantly
enhanced (Figure 2Q). A small but significant increase in activity
was observed for 10 days old Ab1–42 E22G expressing flies treated
with curcumin (Figure 2R). The activity assay was performed with
the unusual population of the Ab1–42 E22G expressing flies
surviving two days longer than T1/2 of the untreated Ab1–42
E22G expressing flies. No activity assay was performed for Ab1–42
E22G expressing flies at ages beyond 10 days, due to their short
lifespan. Tau expressing flies appear severely affected in their
locomotor activity, and interestingly showed a large enhanced
activity during the first hours upon curcumin treatment
(Figure 2U–X). The activity enhancement was sustained with
increasing age, which was different from the Ab transgenes
(Figure 2X). Notably, the Tau expressing flies showed the greatest
increase in locomotor activity of all genotypes upon curcumin
treatment, but as described above, these flies did not show any
significant effect in the lifespan or in climbing behavior upon
curcumin treatment (Figure 1 and. Figure S1).
Histological analysis of amyloid deposits in the
Drosophila brain over time
Drosophila brains were investigated by fluorescence microscopy
using combined antibody and amyloid specific luminescent
conjugated oligothiophene (LCO), p-FTAA, for the presence of
amyloid deposition [29]. Images shown in Figure 3 and Figure S2
represent parts of brains where protein deposition was obvious.
The histological analysis described below was based on visual
inspection of 20 flies of each genotype and is summarized in
Table 1 before the median life span (T1/2) for each genotype.
Control flies with and without curcumin, displayed no antibody or
LCO binding in the brain tissue (Figure 3A–E), but unspecific
staining was seen in the retina and exoskeletal head capsule, as
described before [32]. However, the double inserted Ab1–42
expressing flies showed extensive amyloid staining, with several
Reduced Neurotoxicity by Promoted Fibrillation
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flies (Figure 3F). The amounts of aggregates visible by LCO
staining increased with increasing age (Figure 3F, G, I). Some
staining differences was observed in ten day old flies, where the
untreated flies displayed stronger antibody staining and decreased
LCO staining compared to treated flies (Figure 3G, H, Table 1).
The staining pattern from ten-day-old curcumin treated flies did
not differ from twenty-day-old flies, independent of treatment
(Figure 3G–J). DAPI staining from regions with a high load of
LCO-positive aggregates was decreased, suggesting neuronal loss.
The Ab1–42 E22G expressing flies displayed a spot-like staining from
both LCO and Ab antibody independent of age and treatment,
but a weaker LCO staining than that displayed for wild type single
and double inserted Ab1–42 expressing flies (Figure 3K–O). The
Figure 1. Curcumin affects Drosophila longevity as a function of genotype. Survival trajectories of transgenic C155-Gal4 Drosophila for
different curcumin treatments indicated by: no curcumin added (black lines), 1, 10, and 100 mg curcumin per g yeast paste represented in yellow,
orange, and red lines respectively. (A) Control flies showed a concentration dependent decrease in lifespan upon curcumin treatment. (B) Ab1–40
expressing flies showed reduced survival times when fed intermediate and high curcumin concentrations. (C) Single insert Ab1–42 expressing flies
showed increased survival when treated with low and intermediate curcumin concentrations. (D) Double insert Ab1–42 expressing flies showed an
increased survival for low and intermediate curcumin concentrations. (E) Ab1–42 E22G expressing flies showed increased survival for all curcumin
concentrations. (F) Survival of Tau expressing flies was unaffected at low and intermediate concentrations of curcumin, but revealed a shortened
survival time at the high curcumin concentration. (G) Median survival time of all genotypes with no curcumin added represented in black bars, 1, 10,
and 100 mg curcumin per g yeast paste represented in yellow, orange, and red bars respectively. Significance was compared using a paired student’s
t-test between untreated and treated with curcumin (ns: non-significant; *: P,0.05, **: P,0.01; ***: P,0.001).
doi:10.1371/journal.pone.0031424.g001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31424Figure 2. Curcumin affects Drosophila locomotor activity as a function of genotype. Activity traces (DAM2 system) shown for flies without
(solid line) and with (dotted line) curcumin treatment (10 mg per g of yeast paste), performed 5, 10, 15, and 20 days after eclosion. (A–D) Control flies
showed an activity decrease with increased age. The decreased number of total beam brakes upon increased age was caused due to the shortened
number of active hours. (E–H) Ab1–40 expressing flies showed no improvement in activity upon curcumin treatment. (I–L) In young flies, single insert
Ab1–42 expressing flies showed a higher number of beam breaks and a longer continuation of activity upon curcumin treatment. The effect of
Reduced Neurotoxicity by Promoted Fibrillation
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only slightly with increasing age. The antibody staining decreased
with increasing age. Ab1–40 expressing flies (Figure S2A–E)
displayed weak and restricted LCO and antibody amyloid staining
surrounding the nuclei in twenty-day-old flies. Amyloid staining in
the Ab1–40 expressing flies has never earlier been reported. At
earlier time points, LCO amyloid staining was only shown to a
minute extent, but antibody staining was detected in the areas with
high amounts of cell nuclei (Table 1). There was no difference
between the untreated and curcumin treated flies. Single insert
Ab1–42 expressing flies (Figure S2F) showed antibody staining, as
well as some LCO staining, in both newly eclosed flies and in
untreated ten day old flies. Interestingly, ten-day-old flies treated
with curcumin displayed a different staining pattern than the
untreated flies, where LCO positive aggregates were found in most
regions of the brain that contained cell bodies. The intensity of the
LCO staining appeared enhanced in the curcumin treated flies
(Figure S2G, H). In twenty-day-old flies the difference appeared to
be retained between untreated and curcumin treated flies. Both
untreated and curcumin treated flies had a strong amyloid
staining, predominantly surrounding the nuclei, but regions of
large aggregates were more commonly observed in curcumin
treated flies than in untreated flies (Figure S2I, J, Table 1). The
Tau expressing flies showed few LCO and antibody-binding
aggregates in young flies (Figure S2K–M). At the age of 15 days,
LCO binding aggregates were detected in approximately one out
of five flies. There was no difference in staining upon curcumin
treatment (Figure S2N, O, Table 1). The antibody staining
increased between day 0 and day 10, but decreased in day 15
brains. The aggregates were mostly found in regions were no or
few cell nuclei were visible. The visual inspection of brain histology
rendering assessment of LCO and antibody reactivity respectively
curcumin decreased with increasing age. (M–P) Double insert Ab1–42 expressing flies showed an activity enhancement upon curcumin treatment, but
the effect of curcumin decreased with increasing age. (Q–T) Ab1–42 E22G expressing flies showed an increased number of beam breaks during the
initial hours of monitoring during curcumin treatment, but the number of active hours was not prolonged for 5 days old flies. A small curcumin
induced increase in activity was observed for 10 day old flies. (U–X) Tau expressing flies, at all ages, showed a great enhancement of locomotor
activity during the first hours of experiments upon curcumin treatment. Significance was compared using a paired student’s t-test between untreated
and treated with curcumin (ns: non-significant; *: P,0.05, **: P,0.01; ***: P,0.001).
doi:10.1371/journal.pone.0031424.g002
Figure 3. Curcumin affects the brain amyloid deposition histology patterns as a function of Drosophila genotype. Micrographs of
Drosophila brains taken with 1006objective showing fluorescence from cell nuclei by DAPI (blue), amyloid aggregates by p-FTAA (green) and Ab by
aAb-antibody (red). (A–E) Control flies with and without treatment with curcumin at day 0, day 10, and day 20, showed no antibody or p-FTAA
binding species in the brain tissue. (F–J) Double insert Ab1–42 expressing flies showed extensive amyloid staining by p-FTAA, with several long
extended fibrillar aggregates at all time points. Curcumin treatement accelerated p-FTAA positive (amyloid aggregate) conversion at young age (c.f.
Figure 3G and H). The amount of detectable aggregates increased with age. DAPI staining from regions with widespread p-FTAA-positive aggregates
were decreased. (K–O) Ab1–42 E22G expressing flies at day 0, day 5, and day 10, showed a spot-like staining from both p-FTAA and the Ab specific
antibody, but a weaker p-FTAA staining was apparent (c.f. Fig. 3 I and N). Some irregular nuclei were visible from the DAPI staining. Day 0 and day 5
flies showed protein aggregates detectable with the antibody and to some extent by p-FTAA. The same staining pattern was reveled irrespective of
curcumin treatment. Filled arrowheads show p-FTAA positive amyloid aggregates and open arrows indicate aAb-antibody positive aggregates
(diffuse Ab accumulation). Scale bars in insets represent 20 mm.
doi:10.1371/journal.pone.0031424.g003
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genotype.
Spectral analysis of amyloid formation in Drosophila over
time
Sections stained with the LCO, p-FTAA [29], were analyzed by
hyperspectral imaging. As expected from previous imaging
experiments in Drosophila models, the p-FTAA emission spectrum
ofcompact plaques differed dependingon genotype[32].Weherein
assessed if curcumin treatment rendered a conformational differ-
ence of the amyloid deposits within the Drosophila transgenics. To
this end we employed spectral mixing and quantification of the
fluorescence intensities at 508 nm (excitation at 405 nm) and
612 nm(excitation at560 nm)(FigureS3)asdescribed previouslyin
detail for transgenic APP mice [33]. We used this parameter as an
amyloid fibrillation index. A high ratio of 508/612 nm was
interpreted as a well structured amyloid fibril whereas a low ratio
was interpreted as alternative conformational states of the
aggregates. A spectral shift over time, in presence or absence of
curcumin treatment (0.001%) was clearly observable for the double
inserted Ab1–42 expressing flies (Figure 4A and 4B). Newly eclosed
flies had few aggregates detectable with p-FTAA. The aggregates
had variable emission spectra, resulting in a wide variation in the
amyloid fibrillation index (508/612 ratio values). Some aggregates
with the distinct amyloid feature were also detected already at day 0
(Figure 4A, triangles). The Ab aggregates within the double insert
Ab1–42 expressing flies displayed a higher amyloid fibrillation index,
after ten days of curcumin treatment, indicating that curcumin
promoted a more rapid conversion into more well organized fibrils.
Untreated flies did not display the increased amyloid fibrillation
index at day 10. At day 20, on the other hand, there were no
differences in the amyloid fibrillation index between untreated and
treatedflies.Both groupsoffliesdisplayedahighamyloidfibrillation
index indicating well organized Ab-fibrils. An extended amyloid
fibrillation index in two dimensions (employing also the 543 nm
peak) was also employed for the double inserted Ab1–42 expressing
flies. This analysis further supported the notion that curcumin
treatment promoted amyloid fibrillation into well organized
structures (Figure S4). Control experiments, performing spectral
imaging of curcumin treated flies without p-FTAA staining, did not
result in any spectral images that were above noise level (Figure S5).
Control experiments, where curcumin was used as a histological
labeling agent, did not result in any significant fluorescence in the
spectral imaging (Figure S5), ruling out that the spectral imaging
results were influenced by curcumin fluorescence.
Protein aggregates within aged Ab1–42 E22G expressing flies was
previously shown to display a slightly more red shifted emission
spectrum compared to wild type double insert Ab1–42 expressing
flies [32], as well as in aged mice [33]. This was evident also using
the double excitation hyper spectral imaging method employed
above (c.f. 10 day Ab1–42 E22G expressing flies and 20 day wild type
flies, Fig. 4A and 4C). The emission spectra of the Ab1–42 E22G
expressing flies differed from the double insert Ab1–42 expressing
flies. The wild type double insert Ab1–42 expressing flies showed a
clear double peak of 508 nm and 543 nm, whereas the Ab1–42 E22G
expressing flies only had a shoulder peak at 508 nm for late stage
aggregates [32]. Because the peak at 508 nm increased for double
insert Ab1–42 expressing flies with increased age and increased fibril
formation, it indicates that the Ab1–42 E22G expressing flies do not
produce as well ordered aggregates as the wild type double insert
Ab1–42 expressing flies. Usually the spectra of the Ab1–42 E22G
expressing flieswas redshifted compared tothe double insertAb1–42
expressing flies, and displayed the shoulder peak at 510 nm and the
distinct second peak at 545 nm. Interestingly, the Ab1–42 E22G
expressing flies showed an elevated amyloid fibrillation index in 5
day old flies (Figure 4C and D) compared to the amyloid fibrillation
index at either 0 or 10 day old flies. Even so, no extended fibrous
deposits were visible in the histological staining of Ab1–42 E22G
expressing flies (Figure 3K–O). Both curcumin treated and
untreated flies displayed indifferently the elevated Ab-fibrillation
indexatday5.Atday10the amyloid fibrillationindexwaslowerfor
untreated flies as in the case for wild type expressing flies at day 10
(Fig. 4C, D), albeit with smaller absolute differences than for the
double inserted Ab1–42 expressed flies at this age.
The Tau expressing flies showed significantly more red shifted
emission spectra than either Ab genotypes as reported before [32]
Table 1. Phenotypes of C155-Gal4/UAS-Ab and C155-Gal4/UAS-tau Alzheimer Disease Models of Drosophila treated and untreated
with 0.001% (w/w) of curcumin.
Genotype
Curcumin +/2 control Ab1–40 Ab1–42 Ab1–42;A b1–42 Ab1–42 E22G tau
2 + 2 + 2 + 2 + 2 + 2 +
Survival 3060.4 2460.5 2460.5 2260.6 2060.4 2360.6 1660.6 1860.6 860.2 1460.4 1860.2 1860.5
Climbing 2860.7 2460.5 20606 2260.6 1860.5 2360.6 1660.6 1660.5 860.2 860.2 860.2 860.35
Activity day 5
a 1.000 0.974 0.860 0.831 0.661 0.914 0.495 0.719 0.187 0.269 0.409 0.689
Activity day 10
a 0.823 0.705 0.749 0.851 0.431 0.564 0.260 0.367 0.057 0.104 0.418 0.659
Activity day 15
a 0.671 0.592 0.655 0.719 0.242 0.327 0.160 0.272 n.a. n.a 0.089 0.378
Activity day 20
a 0534 0.538 0.534 0.591 0.177 0.213 0.144 0.176 n.a. n.a n.a. n.a.
a- Ab or Tau reactivity
b 22 +
d +






d + + ++ ++ + + ++ +
d +
d
aDefined as total number of beam brakes for 16 flies in the DAM2 system over 24 h. Flies were reared at 29uC and assayed at the same temperature.
bProtein deposition load determined by visual inspection with a fluorescence microscope of immunofluorescence of antibody detection, of histological sections of
Drosophila heads at day 10 for C155-Gal4/UAS-Ab1–40, C155-Gal4/UAS-Ab1–42, C155-Gal4/UAS-Ab1–42;UAS-Ab1–42, C155-Gal4/UAS-tau; and day 5 for
C155-Gal4/UAS-Ab1–42 E22G. At least 20 fly heads were assayed for each genotype. +++, extensive; ++, intermediate; + detectable; 2, not detected; n.a., not assayed.
cAggregate deposition load determined by visual inspection with a fluorescence microscope of p-FTAA and immunofluorescence of histological sections of Drosophila
heads at day 10 for C155-Gal4/UAS-Ab1–40, C155-Gal4/UAS-Ab1–42, C155-Gal4/UAS-Ab1–42;UAS-Ab1–42, C155-Gal4/UAS-tau; and day 5 for C155-Gal4/UAS-Ab1–42 E22G.A t
least 20 fly heads were assayed for each genotype. +++, extensive; ++, intermediate; + detectable; 2, not detected; n.a., not assayed.
dNot all flies showed protein aggregates, given is the load when protein aggregates were detected.
doi:10.1371/journal.pone.0031424.t001
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amyloid fibrillation index (508/612 nm ratios) at both analyzed
time points (Figure 4E and F). Although the same trend was found
as for the single inserted Ab1–42 expressing flies no significant
spectral difference was observed for the Tau expressing flies upon
curcumin treatment. Due to low detection rate and small
aggregates, resulting in low spectral intensities, no spectra could
be analyzed in Tau expressing flies at day 0.
Quantification of Ab-peptide in aged and curcumin
treated Drosophila
The concentration of Ab is the primary factor determining
aggregation rates and likely also influences Ab conformation
within the formed aggregates. The effect of treating flies with
curcumin on the levels of Ab accumulation was assessed by the
Meso Scale Discovery (MSD) immunoassay, measuring soluble (in
Hepes buffer, pH 7.3) and insoluble Ab (homogenate dissolved in
Hepes buffer, pH 7.3 containing 5 M GuHCl) concentrations in
the brains of flies. Two different lines of flies – double inserted
Ab1–42 expressing flies and Ab1–42 E22G expressing flies – were
examined at three different time points (day 0, 10 and 20 after
eclosion, for double insert Ab1–42 expressing flies, and day 0, 5,
and 10 after eclosion, for Ab1–42 E22G expressing flies).
As anticipated, control flies displayed little signal of Ab
regardless of treatment with curcumin or not (Figure 5A–D,
Table S3, Table S4). For the Ab expressing flies the amount of
total Ab showed no significant difference between the untreated
Figure 4. Curcumin accelerates aggregate to fibril conversion in Drosophila brains. Amyloid fibrillation index as individual spectral shift (A, C,
and E) and mean spectral shift with standard deviation (B, D, and F) over time, in presence (orange) or absence (black) of curcumin treatment for Ab and
Tau expressing flies. (A and B) Newly eclosed double insert Ab1–42 expressing flies had variable emission spectra, resulting in a wide variation in the 508/
612 ratios. Some aggregates with the distinct amyloid feature were also detected (marked with triangles in the graph) in young flies. The double insert
Ab1–42 expressing flies displays a higher amyloid fibrillation index after ten days of curcumin treatment, indicating a more organized fibril formation due
to curcumin ingestion. Untreated flies did not display an increased Ab-fibrillation index at day 10. At day 20, the overall amyloid fibrillation index had
increased, but there were no differences in the amyloid-fibrillation index between untreated and treated flies. (C and D) The Ab1–42 E22G expressing flies
showed a rather high amyloid fibrillation index already in newly eclosed flies. Both treated and untreated flies have higher Ab-fibrillation index at day 5,
but at day 10 the Ab-fibrillation index was lower, especially for untreated flies. (E and F) The Tau expressing flies showed more red shifted emission
spectra than the Ab genotypes, with a higher contribution from the 612 nm emission (560 nm excitation) (Figure S3), resulting in a lower amyloid
fibrillation index. Note the different scale of the y-axis compared to A–D. A few aggregates with elevated amyloid fibrillation index were detected as
marked by triangles in the graph. Overall the trend was the same as for Ab expressing flies but the statistical analysis revealed that no significant
differences were observed for the Tau expressing flies upon curcumin treatment. No spectra could be analyzed in Tau expressing flies at day 0, due to
low detection rate and minute aggregates, resulting in low spectral intensities. (ns: non-significant; *: P,0.05, **: P,0.01; ***: P,0.001).
doi:10.1371/journal.pone.0031424.g004
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the fraction of soluble Ab was not altered by curcumin treatment.
Notably, the fraction of soluble Ab was below 5% of the total Ab
for all genotypes at all time points. We hence concluded that
treatment with curcumin does not shift the total amount of Ab or
the distribution of soluble versus insoluble Ab. This finding
supports the observation that curcumin does not decrease Ab
deposition. It is important to note that any increase in insoluble Ab
due to treatment would be difficult to detect with this assay,
because .95% of Ab was insoluble in untreated flies.
Direct evidence for Ab1–42 binding to curcumin in vitro
It is well established that curcumin in solution at neutral pH is
rapidly degraded [34], and this can also be observed by ocular
inspection of an aqueous curcumin solution (not shown). In our
formulation of curcumin in yeast paste for the fly food we did not
note (by eye) a decrease in yellow coloration over time. We also
noted that in the presence of Ab1–42, curcumin solutions remained
yellow over time. This is in contrast to observations of curcumin
dissolved alone in PBS [34]. An absorbance assay was performed
at 29uC to quantify this effect. In the absence of Ab1–42 we
observed a rapid decline in absorbance at 440 nm over time, with
a half time of 1.5–3 h, depending upon curcumin concentration
(Figure 6A–C). In the presence of Ab1–42 this decline in
absorbance was abolished at curcumin concentrations below that
of Ab1–42. In addition, we observed a noticeable red shifted
absorbance spectrum of curcumin in the presence of excess Ab1–42,
supporting the notion of sequestered curcumin molecules in a
Figure 5. The amount of Ab-peptide accumulation in Drosophila brain is not affected by curcumin. Quantification of Ab-peptide in aged
flies was performed using the Meso Scale Discovery (MSD) immunoassay. Soluble and insoluble Ab concentrations for untreated flies (black bars) and
curcumin treated flies (orange bars). (A) The double insert Ab1–42 expressing flies showed an increased signal of Ab compared to controls at all time
points in the soluble fraction. There was no significant difference in the curcumin treated or untreated flies. (B) The double insert Ab1–42 expressing
flies showed an increased signal, at all time points, of Ab compared to controls. The insoluble fraction accounted for the majority of Ab, but there was
no significant difference in Ab concentration between untreated flies and curcumin treated flies. (C) Ab1–42 E22G expressing flies showed an increased
signal of Ab compared to controls at day 5 and day 10 in the soluble fraction. There was no significant difference in soluble Ab of curcumin treated
flies, when compared to untreated flies. (D) The Ab1–42 E22G expressing flies showed an increased signal of Ab when compared to controls at all time
points in the insoluble fraction, but there was no significant difference in Ab concentration between untreated flies and curcumin treated flies. Error
bars denote the mean standard deviation as deduced from triplicate samples in three independent experiments. (ns: non-significant; *: P,0.05,
**: P,0.01; ***: P,0.001).
doi:10.1371/journal.pone.0031424.g005
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substantiate two important findings: i) Ab1–42 directly binds
curcumin (evident by the spectrochromic absorbance shift) and ii)
Ab1–42 sequesters curcumin from degradation (evident by the
preserved curcumin absorbance over time).
In vitro aggregation of Ab1–42 in the presence of
curcumin
Next, to compare our data with previous reports (e.g. [9]), we
performed in vitro studies to address the effect of curcumin on the
molecular aggregation behavior of Ab1–42. Samples were assayed
using native PAGE Western blotting, transmission electron
microscopy (TEM), and p-FTAA fluorescence. Native PAGE
separation of freshly dissolved Ab1–42 showed the presence of
monomeric Ab1–42 and a diffuse band representing soluble
oligomeric Ab1–42 for all samples (Figure 7A). Native PAGE
separation performed of the samples from the in vitro fibrillation at
60 minutes displayed an enhancement of insoluble Ab1–42 in
presence of curcumin, when compared to the control incubated
with vehicle (1% ethanol). The enhanced band of insoluble
material was observed at early time points, 60 minutes, with larger
aggregates not being able to penetrate into the separation gel. This
insoluble material appeared to increase at the expense of soluble
oligomers and monomers. At longer fibrillation times, 180 min-
utes, the presence or absence of curcumin did not result in any
difference in the amount of large aggregates nor oligomers or
monomers. Even though TEM is not a quantitative method, TEM
analysis was performed to obtain a morphological assessment of
how curcumin influenced Ab1–42 aggregation. Micrographs
obtained for Ab1–42 incubated for 60 minutes in the absence of
curcumin displayed a great amount of morphologically disordered
aggregates, as well as few amyloid fibrils associated with the
aggregates. In the presence of curcumin, even at the lowest
concentration, it appeared that the amount of fibrils was
enhanced. At 180 min, large networks of entangled fibrils were
present in all samples. Taken together, the PAGE and TEM
analysesshowedthatcurcumindoesnotinhibitfibrillationofAb1–42,
but on the contrary appeared to enhance fibrillation. A fluorescence
based assay, using p-FTAA as a probe for formation of prefibrillar
aggregates (including amyloid oligomers) and amyloid fibrils
[29,35], was also performed. Conducting this assay in the presence
of curcumin is difficult, because curcumin re-absorption of light will
decrease the fluorescence signal and also competition between
binding sites can occur. Hence, at least to accommodate the first
reservation the fluorescence intensity was normalized for each
curcumin concentration. As shown previously, p-FTAA fluoresces
strongly in the presence of prefibrillar aggregates, and in the
presence of only vehichle (2% EtOH) Ab1–42 rapidly forms p-FTAA
positive aggregates with a plateau at 60–240 min, followed by a
decreased signal (Figure 7D and Figure S7). Interestingly, the
presence of curcumin appeared to suppress the formation of the
initial prefibrillar phase, in a concentration dependent manner.
These results support the notion that curcumin shifts the Ab1–42
fibrillation pathway away from prefibrillar aggregates/oligomers
and towards amyloid fibrils.
Discussion
In the present work we aimed to formulate a pharmacological
treatment study of Drosophila AD models. The compound
curcumin was selected from its well documented ability to be
non-toxic, to mitigate neuropathology and to prevent cytotoxic Ab
aggregate accumulation. A recent study by Alavez and colleagues
in Caenorhabditis elegans shows the promise of curcumin (and
Thioflavine T) as a drug candidate towards protein misfolding
during aging and Ab3–42 amyloidosis [36]. Our findings in
Drosophila are rather different than that reported in the Alavez
study. In C. elegans, no toxic effects were found on control worms,
but rather a life enhancing effect. Furthermore, curcumin treated
Figure 6. Direct evidence for Ab1–42 binding in vitro. (A–C) Curcumin degradation at neutral pH (PBS) solution over time assessed by
absorbance at 440 nm for solutions containing 0.0001% (yellow), 0.001% (orange), and 0.01% (red) (w/v) curcumin. Solid lines and dotted lines
represented in presence and in absence of 10 mMA b1–42 peptide respectively. Black lines represents background absorbance of buffer (dotted line)
and 10 mMA b1–42 peptide (solid line) in the absence of curcumin. (D–F) Curcumin absorbance spectra for the corresponding curcumin containing
samples as those described in A–C at 0 h, 2 hours and 10 hours of incubation colored in gray scale.
doi:10.1371/journal.pone.0031424.g006
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mechanistic outcome from our study was hence quite different
even though the message is the same: curcumin prolongs lifespan
and reduces neurodegeneration in an invertebrate model system
for Ab amyloidosis.
As anticipated from previous reports on the potency of curcumin,
the lifespan and activity behavior of AD fly models treated with
curcumin displayed a positive pharmacological effect. Unexpected-
ly, control flies exhibited a substantially reduced survival as a
function of curcumin concentration. Importantly, the pharmaco-
logical effect was directly dependent on genotype, rendering the
strongest positive curcumin effect on Ab expressing flies exhibiting
the worst phenotype. The curcumin induced pharmacological effect
was in the following order: Ab1–40,single insert Ab1–42,double
insert Ab1–42,Ab1–42 E22G. Intriguingly the reverse order of
curcumin toxicity was evident: control.Ab1–40.single insert
Ab1–42.double insert Ab1–42.Ab1–42 E22G. This became most
evident when comparing the median life span of the different
genotypes as a function of curcumin concentration (Figure S8).
Hence the marked toxicity of curcumin for Drosophila controls was
decreased or totally depleted for the amyloid expressing trangenes,
indicating that Ab (and possibly also Tau) can function as a chemical
detoxifier. If this is a normal function of Ab amyloid is not known,
but, in the context of other Ab xenobiotic systems, a copper
detoxification role within the context of transgenic Caenorhabditis
eleganswasrecentlyreported[37].Wecannotruleouteffectsonother
molecular pathways compared to direct binding to Ab,h o w e v e rw e
have shown that Ab1–42 does bind curcumin in vitro.I ti st h e r e f o r e
particularly interesting that Ab appeared to suppress curcumin
induced toxicity in the flies. It is hence possible that curcumin
metabolites are responsible for the induced toxicity noted in the fly,
and that this toxic effectwas hindered by its sequestration within Ab.
Figure 7. In vitro fibril conversion of Ab1–42 is accelerated by curcumin. Aliquots of fibrillation reactions (10 mMA b1–42 in 10 mM phosphate
pH 7.5, 37uC, agitation) were assayed at 0, 60 and 180 min. (A) Native-PAGE separation was interpreted as differential separation of monomeric,
oligomeric and insoluble Ab1–42. Lower populations of oligomeric species and elevated amounts of insoluble Ab1–42 was observed in curcumin
containing samples. (B) Transmission electron micrographs obtained at 60 minutes in the absence of curcumin revealed the presence of
morphologically disordered aggregates with associated amyloid fibrils, whereas all concentrations of curcumin revealed the presence of amyloid
fibrils. (C) At 180 minutes all samples contained extensively fibrillated Ab1–42. Scale bars represent 100 nm. (D) p-FTAA fluorescence kinetics assaying
formation of prefibrillar Ab1–42 aggregates in the presence of vehicle (2% EtOH) and/or 0.0001, 0.001, and 0.01% (w/v) curcumin (0.27–27 mM
curcumin). The concentration dependent suppression of the rapid prefibrillar phase, suggests accelerated conversion of Ab1–42 to amyloid fibrils in
the presence of curcumin. Absence of curcumin is represented with black line, 0.0001, 0.001, and 0.01% (w/v) curcumin is represented in yellow,
orange, and red lines respectively.
doi:10.1371/journal.pone.0031424.g007
Reduced Neurotoxicity by Promoted Fibrillation
PLoS ONE | www.plosone.org 10 February 2012 | Volume 7 | Issue 2 | e31424The increased lifespan upon curcumin treatment was especially
striking for flies expressing the Ab peptide with the so called Arctic
mutation; Ab1–42 E22G.T h eA b1–42 E22G expressing flies increased
their median survival with a striking 75% for the intermediate
curcumin concentration. In the survival assay no positive effect on
curcumintreatmentswasobservedforTauexpressingflies,butrather
a toxic effect at the highest curcumin concentration. Nevertheless the
flies expressing Tau showed sustained locomotor activity and the
largest increase in activity of all genotypes upon curcumin treatment
at the intermediate concentration. This enhanced activity was
sustained over time, in contrast to treatment of Ab transgenes,
suggesting a different mechanism, possibly related to decreased
oxidative stress [38,39] arising from antioxidant activity of curcumin.
Histological staining of fly brains followed by visual inspection
showed that the treatment with curcumin at the intermediate
concentration appeared to accelerate the formation of Ab amyloid
fibrils (p-FTAA positive), as opposed to those reactive with Ab
specific antibody. This was evident by analysis of the protein
aggregation progression by microscopy at different ages (Table 1).
At later time points (close to the day of death) the difference was less
pronounced, but most importantly no decrease in total amount of
amyloid deposition was observed as a function of curcumin
treatment. In this fly model .95% of accumulated Ab1–42 is
insoluble, and a redistribution of soluble/insoluble Ab1–42 can only
be quantified if the soluble fraction was to increase during curcumin
treatment. Our data showed that curcumin treatment did not affect
the amount or the soluble/insoluble distribution of Ab deposition as
quantified by the MSD immunoassay. Furthermore, aged flies
expressing the Ab1–42 peptides in the eyes by a strong driver (GMR-
Gal4 crossings), analyzed by histological staining in the fluorescence
microscope after staining with antibody, the LCO, and the nuclear
markerDAPI,alsodisplayedindifferentamyloiddepositionpatterns
upon curcumin treatment (Figure S9). Taken together, in neither of
our experiments did we observe any decrease in the amount of Ab
or Tau deposition following curcumin treatment.
One striking finding in this study was the hyper spectral analysis
of p-FTAA fluorescence over time performed on double insert
Ab1–42 expressing flies: curcumin treatment accelerated the
formation of well ordered amyloid fibrils in middle age. The
notion that curcumin accelerated conformational conversion,
rather than modulating the levels of Ab, was hence supported
by the quantification of similar amounts of Ab in both treated and
untreated brains. Our observations support recent findings in
transgenic AD mouse models [20] and in vitro experiments [40],
where it has been suggested that curcumin modulates the Ab
amyloid cascade by accelerating fibril formation and decreasing
oligomer formation (Figure 8). Fibrillation assays of recombinant
Ab1–42 peptide in absence and presence of curcumin was
performed in order to verify such activity of the curcumin used
in our Drosophila assay. The in vitro fibrillation assays of
recombinant Ab1–42 peptide in our study hence confirmed the
few previous reports that curcumin decrease the population of
soluble oligomers and appeared to accelerate formation of large
amyloid fibrils in contrast to the majority of reports stating the
fibrillation inhibitory mechanism for curcumin.
The Arctic mutant peptide Ab1–42 E22G is well established to
form soluble oligomeric protofibrils with high cytotoxicity [41],
and is likely the reason for its strong toxicity in Drosophila [3,5].
The finding that sub-stoichiometric amounts of curcumin stabilize
nucleation of fibril formation in vitro correlates very well with the
notion that reduced oligomerization and increased fibril formation
in the presence of curcumin markedly protects the Ab1–42 E22G
expressing flies. Our findings in the fly correlates well with those
previously reported using mutagenesis where one additional
mutation Ab1–42 I31E in the context of Ab1–42 E22G, mitigated
neurotoxicity in Drosophila by enhancement of amyloid fibril
conversion at the expense of oligomers [42]. The same mechanism
could explain the neuroprotective effect of curcumin seen for the
wild type Ab expressing flies.
Concluding remarks and outlook
Expressing Ab in the Drosophila CNS results in a significant
neurotoxic effect, in contrast to that observed in mouse models of
AD, which indicates the potency of these models for pharmaco-
logical treatment studies.We have demonstrated that curcumin
exerts a general neuroprotective effect for Ab and tau Drosophila
transgenes. We have demonstrated that this curcumin activity in
the context of Ab is due to accelerated fibril conversion at the
expense of putatively neurotoxic oligomers. It is plausible that the
apparent toxicity of curcumin within Drosophila, which appears to
be absent for mammalian cells, does suggest that the neuropro-
tective effect of curcumin can be even stronger than that reported
here. The main drawback for curcumin as a drug for treatment of
AD appears to be the poor bioavailability and stability in solution.
With that in mind it is encouraging that curcumin analogues are
synthesized as candidate drugs towards AD [43].
Materials and Methods
Fly stocks
Drosophila stocks were allowed to develop under a 12:12 hours
light:dark cycle until eclosion at 26uC and posteclosion at 29uC, at
Figure 8. Schematic illustration of Ab aggregation in Drosophila. The aggregation from soluble Ab monomer to Ab oligomers (step 1) and
further maturation to Ab amyloid fibrils (step 2) is dependent on age. The Arctic mutation (E22G) favors the formation of oligomers. In the presence
of curcumin, the aggregation into Ab amyloid fibrils (step 2) is favored.
doi:10.1371/journal.pone.0031424.g008
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standard Drosophila food (corn meal, molasses, yeast, and agar) and
maintained post eclosion in 50 ml plastic vials containing 7 ml
agar (20 g agar, 20 g sugar dissolved in 1 l of milliQ water) and
yeast paste (dry bakery yeast dissolved in milliQ water) at 29uC
under 12:12 hours light-dark cycles, in a setup of twenty flies per
vial. The vials were changed every second day. Curcumin (28260,
Fluka) was dissolved in 95% ethanol to a concentration of 10 mg/
ml and then diluted into the yeast paste into a final concentration
of 1, 10 and 100 mg curcumin per g yeast paste, corresponding to
(w/w) 0.0001%, 0.001%, and 0.01% curcumin added. Even
distribution of curcumin within the yeast paste was easily checked
by visual inspection due to the strong yellow color of the
compound. All three curcumin concentrations were used in the
lifespan and climbing assays, but only the intermediate concen-
tration of 10 mg curcumin per g yeast paste was used in the activity
assay, for flies corresponding to the immunohistochemistry
combined with LCO staining, and for flies corresponding to
quantification of Ab levels by MSD. The C155-Gal4 driver [44]
was used for all experiments except for the eye degeneration assays
were the GMR-Gal4 driver [45] was used instead. The UAS
transgenes used in the experiments were Ab1–40 (UAS-Ab1–40),
single insert Ab1–42 (UAS-Ab1–42), double insert Ab1–42 (UAS-Ab1–42;
UAS-Ab1–42), Ab1–42 E22G (UAS-Ab1–42 E22G) [3], and tau
(UAS-tau) [1].
Survival Assay
The survival assay is a standard assay for monitoring the effect
of genotype or environmental conditions on Drosophila lifespan,
and is especially useful for C155-Gal4 lines expressing toxic
proteins in the CNS. The number of surviving flies corresponding
to the C155-Gal4 crossings was counted every second day. The
survival proportions were calculated using the Kaplan-Meier
estimation [46] by using the log-rank method in the GraphPad
Prism 5.0 d software (GrapPad Software Inc., San Diego, CA,
USA). The survival times described in the study are given as
median 6 standard error of the median. The number of flies in the
assay was between 100 and 60 flies of each genotype, as specified
in Table S2. Significance was compared using a paired student’s t-
test between untreated (0% curcumin) and treated with curcumin
(*: P,0.05, **: P,0.01; ***: P,0.001).
Drosophila Locomotor Activity Assay
The activity of individual flies (n=16) corresponding to the
C155-Gal4 crossings was recorded using Drosophila Activity
Monitors (DAM2, TriKinetics, Waltham, MA, USA), and the
number of beam breaks per hour during 24 hours was registered.
The DAM2 unit was placed with a light source at the front of the
monitor. The assay started with 10 hours of light followed by
12 hours in the dark, and 2 hours of light. The activity was
measured at 5, 10, 15, and 20 days after eclosion for all genotypes
and curcumin treatments, except for Ab1–42 E22G expressing flies
and the Tau expressing flies, which was only measured for 5–10
and 5–15 days, respectively, due to their shortened lifespan. The
total number of beam breaks were calculated for all genotypes and
curcumin treatments and compared using two-tailed student’s t-
test of unpaired samples (*: P,0.05, **: P,0.01; ***: P,0.001)
with GraphPad Prism 5.0 d software (GrapPad Software Inc., San
Diego, CA, USA).
Histological Analysis of Amyloid
Mildly fixed sections of Drosophila brains were assayed by
histological staining for the presence of amyloid deposits using a
combination of immunofluorescence and the amyloid specific
luminescent conjugated oligothiophene (LCO), p-FTAA (49,3--
Bis-carboxymethyl-[2,29;59,20;50,2-;5-,200]quinquethiophene-5,500-dicar-
boxylic acid) [29]. The amyloidotropic p-FTAA is a conformational-
dependent probe with a flexible structure that can serve as a
surrogate marker to reveal heterogeneity among amyloid deposits
in a manner analogous to that reported for luminescent
conjugated polythiophenes (LCP) [47,48,49]. Newly eclosed, ten,
and twenty day old flies corresponding to the C155-Gal4 and
newly eclosed and twenty day old flies corresponding to the GMR-
Gal4 crossings were mounted in Tissue-TekH O.C.T. Compound
(4583, Histolab, Sweden). The C155-Gal4 crossings were used to
study amyloid aggregation over lifetime, and the GMR-Gal4
crossings were used to study late stages of amyloid aggregation
independent of genotype lifespan. The fly heads were sectioned
and stained during standard procedures [32]. The C155-Gal4/
UAS-Ab1–42 E22G and C155-Gal4/UAS-tau were mounted at day 0,
day 5, and 10 and at day 0, day 10, and 15 respectively due to
their shortened lifespan. The late time points approximately
correspond to their T1/2, and the earlier time point approximately
correspond to half of the time for their T1/2. For protein detection
monoclonal mouse anti-b-Amyloid (3740-5-100, Mabtech, Swe-
den) diluted 1:200 in 4% BSA/PBST (PBS with 0.1% Triton-X
100) and monoclonal mouse anti-human PHF-Tau AT8
(MN1020, Pierce Endogen) diluted 1:100 in 4% BSA/PBST and
visualized using donkey anti-mouse Alexa FluorH 594 (A21203,
Invitrogen Molecular Probes) diluted 1:500 in 4% BSA/PBST. As
amyloid specific probe the LCO; p-FTAA [29], diluted 1:500
(from a 1 mg/ml stock) in PBS was used. The sections were
stained by the nuclear marker DAPI by using VectashieldH with
DAPI (H1200, Vector laboratories, Burlingame, CA, USA) as
mounting medium. An Inverted fluorescence microscope (Carl
Zeiss Inc.), with 405/30 nm, 470/40 and 546/12 nm longpass
filter or a fluorescence microscope (Leica Microsystems Inc.,
Bannockburn, IL, USA), with 405/40 nm, 436/20 and 560/
40 nm longpass filter, both attached with a spectral camera
(Applied Spectral Imaging Inc.) were used to obtain the
micrographs.
At least 20 fly heads of each genotype that had been fed normal
food or food containing 0.001% w/w curcumin (10 mg per gram of
yeast) were assayed. An estimation of the aggregate load in each
genotype was done by visual inspection in the fluorescence
microscope.
Spectral analysis of amyloid produced in Drosophila
Consecutive sections to the histological analyses was used for
protein spectral analyzes by the use of the LCO; p-FTAA [29,32].
The p-FTAA was diluted 1:500 (from a 1 mg/ml stock solution) in
PBS and was used to stain sections as described before [32]. A
fluorescence microscope (Leica Microsystems Inc., Bannockburn,
IL, USA), with 405/40 nm and 560/40 nm longpass filter,
attached with a spectral camera (Applied Spectral Imaging Inc.)
was used to collect spectral images in an interval of 450 to 700 nm.
LCO hyper spectral microscopy analysis of Drosophila brain
aggregates was used to evaluate the conformation of deposited
Ab and Tau. The ratio of the emission peak at 508 nm and the
emission peak at 612 nm for the LCO, p-FTAA, taken at 405 nm
excitation and 560 nm excitation (Figure S3) was plotted as an
amyloid fibrillation index. Spectral analysis of the two excitation
spectra was performed by the SpectraViewH software (Applied
Spectral Imaging Inc.) and were further analyzed by the
GraphPad Prism 5.0 d software (GrapPad Software Inc., San
Diego, CA, USA). The spectral shift of the LCO was analyzed by
the fraction of the blue shifted peak (at 508 nm from the 405 nm
excitation) and the red shifted peak (at 612 nm from the 560 nm
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fraction with the standard deviation and compared using two-
tailed student’s t-test of unpaired samples (*: P,0.05, **: P,0.01;
***: P,0.001).
To distinguish between different forms of aggregates formed in
the double inserted Ab1–42 expressing flies corresponding to the
C155-Gal4 crossing in absence or presence of curcumin at different
ages, the fraction of the peaks at 508 nm and 543 nm verses the
peaks at 508 nm and 612 nm were analyzed by the GraphPad
Prism 5.0 d software (GrapPad Software Inc., San Diego, CA,
USA). The spectral shifts were estimated as the medium fraction
with the standard deviation and compared using two-tailed
student’s t-test of unpaired samples (*: P,0.05, **: P,0.01;
***: P,0.001).
At least five different brains of the different genotypes at
different time points were analyzed. The number of spectra taken
was dependent on amount of amyloids detected. At least 15
spectra were collected of every genotype at the different time
points.
Quantification of the Ab1–42-peptide in aged Drosophila
Five fly heads of newly eclosed, ten and twenty day old double
inserted Ab1–42 expressing flies and newly eclosed, five and ten day
old Ab1–42 E22G expressing flies, both corresponding to the C155-
Gal4 crossing, were homogenized in 50 ml of extraction buffer
(50 mM Hepes pH 7.3, 5 mM EDTA, Protease inhibitor
(Complete
TM, Roche Diagnostics)). The homogenate was incu-
bated at room temperature for 10 min, sonicated for 4 minutes in
a water bath and then centrifuged at 12 000 g for 5 minutes into a
‘‘soluble’’ and ‘‘insoluble’’ fraction. 20 ml of the supernatant
(‘‘soluble fraction’’) was mixed with 180 ml hepes dilution buffer
(25 mM Hepes pH 7.3, 1 mM EDTA, 0,1% MSD Blocker A
(R93BA-4, Meso Scale Discovery, MD, USA)). The pellet
(‘‘insoluble fraction’’) was homogenized in 50 ml of extraction
buffer containing guanidinium HCl (5 M GnHCl, 50 mM Hepes
pH 7.3, 5 mM EDTA, Protease inhibitor (Complete
TM, Roche
Diagnostics)). 20 ml of the supernatant of the ‘‘insoluble fraction’’
was mixed with 180 ml hepes dilution buffer prior to analysis. All
homogenate samples were assayed in triplicates at three
independent assay occasions.
The quantification of Ab-peptides in the ‘‘soluble’’ and
‘‘insoluble’’ fractions were performed using the MSDH 96-Well
MULTI-ARRAYH Human (6E10) Abeta 42 Ultra-Sensitive Kit
(K151FUE-2, Meso Scale Discovery, MD, USA). Triplicate 25 ml
aliquots of sample were mixed with an equal amount of MSD
Blocker A (2% MSD Blocker A, 0.2% Tween 20 and protease
inhibitor) and added to a MSD MULTI-SPOTH 96-well 4-spot
plate. Detection was achieved by addition of 25 ml1 mg/ml
SULFO-TAG (R91AN-1, Meso Scale Discovery, MD, USA) 4G8
monoclonal antibody (SIG-39220-200, Nordic Biosite, Taby,
Sweden) for C155-Gal4/UAS-Ab1–42;UAS-Ab1–42, or SULFO-
TAG Anti Ab42 antibody (D0011750, Meso Scale Discovery,
MD, USA) for C155-Gal4/UAS- Ab1–42 E22G, and measurements
were taken in a SECTOR Imager 2400 instrument (Meso Scale
Discovery, MD, USA). To adjust for variation in the protein
extraction step a quantitation of the total amount of protein from
each sample of fly homogenate was performed by usage of the Bio-
Rad DC Protein Assay Kit II (500-0112, BioRad, CA, USA). The
concentrations of Ab were compared between untreated flies and
flies treated with curcumin (10 mg per gram of yeast). Significance
was calculated using two-tailed Student’s t-test (*: P,0.05,
**: P,0.01; ***: P,0.001) in the GraphPad Prism 5.0 d software
(GrapPad Software Inc., San Diego, CA, USA).
In vitro Fibrillation Assay
Recombinant Ab1–42 HFIP (A-1163-2, rPeptide, Borgart, GA,
USA) was dissolved in 2 mM NaOH into a concentration of
1 mg/ml (222 mM). The peptide was stored at 220uC. 10 mM
Ab1–42 HFIP was allowed to fibrillate in a 96-well assay plate
(3915, Corning Inc., NY, USA) in 10 mM phosphate buffer
pH 7.5 in the absence or presence of curcumin in concentrations
of 0.27, 2.7, and 27 mM dissolved in EtOH (corresponding to (w/
w) 0.0001%, 0.001%, and 0.01% added curcumin). The
fibrillation was performed at 37uC, at 500 rpm. Aliquots were
withdrawn at time points of 0, 60, and 180 minutes and were
assayed by Western blotting (see below) and transmission electron
microcopy (see below). The p-FTAA fluorescence assay was
performed as described in [29].
Native PAGE Western blotting
15 ml aliquots from the fibrillation assay at time points; 0, 60,
and 180 minutes, were mixed with 15 ml Native sample buffer
(161-0738, BioRad, CA, USA) and run on a 12% acrylamide gel
during native condition. Pre-stained protein standards (161-0374,
BioRad, CA, USA) and synthetic Ab1–42 peptide were used to
indicate the apparent molecular weights of peptides and
aggregates. After electrophoresis, proteins were blotted onto
Immobilon–P transfer membrane (IPVH00010, Millipore, Bill-
erica, MA, USA) set at 100 V for 1 hours at room temperature.
After transfer, membranes were rinsed in distilled water followed
by blocking using 4% BSA/TBST (TBS with 0.1% Tween) for
2 hours at room temperature. Blocked membranes were incubated
with Monoclonal mouse anti-Amyloid b1–16 (6E10) antibody
(9320-02, Signet Laboratories Inc., Dedham, MA, USA) diluted
1:10 000 in 4% BSA/TBST for 1 hours at room temperature.
After incubation with primary antibody, membranes were washed
three times for 10 minutes in TBST, incubated with alkaline
phosphatase-conjugate anti-mouse IgG (ab6729-1, AbCam, Cam-
bridge, MA, USA), diluted 1:1 000 in 4% BSA/TBST for
30 minutes at room temperature, and washed again three times
for 10 minutes in TBST. The membrane was developed using
Immun-Star
TM Chemiluminescent (170-5012, BioRad, CA, USA)
and visualized using a LAS-400mini attached with a CCD-
camera (Fujifilm corporation, Greenwood, SC, USA). The in vitro
fibril formation assay was repeated at three different occasions
with fresh solutions.
Transmission Electron Microscopy
5 ml aliquots from the fibrillation assay at time points; 0, 60, and
180 minutes, were applied on formvar and carbon coated copper
grids for transmission electron microscopy (Carbon-B copper
grids, Ted Pella Inc., Pedding, CA, USA). The sample was allowed
to adhere to the grid for two minutes at room temperature. The
grid was washed with dH2O and incubated for 20 seconds with
5 ml 1% uranyl acetate. Transmission electron micrographs were
taken using a Jeol-1230 electron microscope operating at 100 kV.
Supporting Information
Figure S1 Climbing fraction trajectories of different
transgenic Drosophila for different curcumin treat-
ments. (A) Control flies showed decreased climbing activity
during aging upon curcumin treatment. (B) Curcumin treatment
of Ab1–40 expressing flies showed a positive effect for low curcumin
concentration and a toxic effect for the high curcumin concen-
tration. (C) Curcumin treatment of single insert Ab1–42 expressing
flies showed a positive effect for the intermediate curcumin
concentration. (D) Curcumin treatment of the double insert Ab1–42
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behavior but was non-significant for the T1/2 climbing. (E) Ab1–42
E22G expressing flies showed an increased climbing ability for all
curcumin concentrations. (F) Tau expressing flies showed no
significant effect on the climbing behavior upon curcumin
treatments. Symbols: No curcumin added represented with
black lines, 1, 10, and 100 mg curcumin per g yeast paste
represented in yellow, orange, and red lines respectively. (G)
Median time of climbing fraction of all genotypes with no
curcumin added represented in black bars, 1, 10, and 100 mg
curcumin per g yeast paste represented in yellow, orange, and red
bars respectively.
(TIF)
Figure S2 Curcumin affects the brain amyloid deposi-
tion histology patterns as a function of Drosophila
genotype. Micrographs of fly brains taken with 1006 objective
showing fluorescence from cell nuclei by DAPI (blue), amyloid
aggregates by p-FTAA (green) and Ab by aAb-antibody (red). (A–
E) Ab1–40 expressing flies with and without treatment with
curcumin at day 0, day 10, and day 20, displayed small
perinuclear amyloid deposits at day 20. Earlier time points show
protein aggregates recognized by the antibody, and to a minimal
extent with p-FTAA. (F–J) Single insert Ab1–42 expressing flies
exhibited strong amyloid staining by p-FTAA, predominantly
surrounding the nuclei at day 20 as well as for curcumin treated
flies at day 10. At day 0, and untreated flies at day 10 showed
protein aggregates recognized by the antibody, and to some extent
with p-FTAA. (K–O) Tau expressing flies at day 0, day 5, and day
10 displayed p-FTAA and anti-Tau-positive aggregates. The
aggregates were mostly found in regions were no or few cell nuclei
were visible. Filled arrowheads show p-FTAA positive (amyloid
aggregates) and open arrows indicate aAb or aTau-antibody
positive (diffuse Ab/Tau accumulation). Scale bars represent
20 mm.
(TIF)
Figure S3 Hyperspectral imaging of in vivo formed Ab
aggregates over time. Spectral analysis of aggregates per-
formed as in Figure S6, of double insert Ab1–42 flies at different
ages. (A) Newly eclosed double insert Ab1–42 flies have few and
small aggregates detectable with p-FTAA with variable added
emission spectra. The contribution from the 508 nm peak (405/40
excitation) was commonly smaller than from the 612 nm peak
(560/40 excitation). (B) At day 10, the double insert Ab1–42 flies
shows extensive Ab aggregation, detectable with p-FTAA. The
spectra of the aggregates showed a high contribution of the
508 nm peak (405/40 excitation) and a low contribution of the
612 nm peak (560/40 excitation). The shoulder peak at 508 nm
was clearly visible, but was consistently much lower than the peak
at 543 nm. This is likely an indicator of immature fibrils. (C) At
day 20, the double insert Ab1–42 flies have large aggregates formed
that are clearly recognized by the LCO with added a more distinct
double peak at 508 and 543 nm, indicating well organized
amyloid fibrils.
(TIF)
Figure S4 2D spectral analysis of amyloid in double
insert Ab1–42 expressing Drosophila showing accelera-
tion of fibrillation by curcumin ingestion. The fraction of
the emission peak at 508 nm and the emission peak at 543 nm and
the fraction of the emission peak at 508 nm and the emission peak
at 612 nm of the LCO, p-FTAA, taken at 405/40 nm excitation
and 560/40 nm excitation was plotted as a 2D amyloid fibrillation
index. (A) The variable emission spectra from newly eclosed flies,
resulted in a wide variation in the 2D amyloid fibrillation index,
interpreted as a wide variation in the morphology of the
aggregates. (B) After ten days there was still a variation in
aggregate spectra detected by the LCO in untreated flies but with
a shift towards low 508/612 nm ratios. (C) After ten days of
curcumin treatment, the spectra were less wide spread and shifted
towards higher 508/612 nm ratios indicating more well ordered
aggregate morphology. At day 20, both untreated (D) and
curcumin treated (E) flies showed the grouped 2D amyloid
fibrillation indexes indicating amyloid fibrils with the same
morphological structure as those observed in curcumin treated
day 10 flies.
(TIF)
Figure S5 Binding control of curcumin to histological
sections of double insert Ab1–42 expressing Drosophila at
day 20. (A) Curcumin fed control flies (0.001%) only stained with
DAPI as nuclei marker, shows no specific curcumin staining (D)
Curcumin fed double insert Ab1–42 flies (0.001%) only stained with
DAPI as nuclei marker, shows no specific curcumin staining of
amyloid. The integration time for the green channel (470/40) was
set to maximum (3 s) to enhance the intensity for the channel. This
produced an over-bleed from the DAPI staining into the green
channel (open arrows). (B) Curcumin (0.01% in ethanol) staining
as a histological marker of amyloid in unfed control flies combined
with DAPI staining for nuclei marker and (E) double insert Ab1–42
flies, shows spot like appearance from precipitated compound for
both control flies and Ab expressing flies (open arrow in B). (E)
Some amyloid was detected in Ab expressing flies (arrow), but the
fluorescence emission was too low from the aggregates to confirm
if the emitted light represent the bound curcumin to Ab aggregates
and were only detected as background in the 470/40 excitation
filter. (C) Curcumin staining of unfed control flies followed by p-
FTAAstaining combined with DAPI staining, shows no amyloid
staining in controls but in (F) Ab expressing flies. Since the
curcumin histological staining increased the background staining
of the samples, the large aggregates were still detected by the LCO
probe (arrow head), but smaller aggregates surrounding the
nuclei’s were more diffuse (arrow). The emission spectra from
the 470/40 excitation showed typical p-FTAA spectra in (F). No
excitation of the 405/30 filter was possible due to the DAPI
staining, and the characteristic double peak of the p-FTAA was
hence lacking.
(TIF)
Figure S6 Spectral contribution for Ab and Tau aggre-
gates found in Drosophila. A fluorescence microscope, with
405/40 nm and 560/40 nm longpass filter, attached with a
spectral camera was used to collect hyper spectral images in an
interval of 450 to 700 nm of aggregates found in brain tissue
stained with the LCO, p-FTAA. Spectral additions of the two
excitations was performed by the SpectraViewH software. The
spectral shift of the LCO was analyzed by the fraction of the peak
at 508 nm from the 405/40 nm excitation setup, and the peak at
612 nm from the 560/40 nm excitation. For 2D analysis of the Ab
deposits, the peak at 543 nm, from the 405/40 nm excitation was
used.
(TIF)
Figure S7 Fluorescence based assay using p-FTAA as a
probe for recombinant Ab aggregation. Raw data graph
corresponding to Figure 7D in main article, with error bars
represented SEM. No curcumin added (vehicle control 2% EtOH)
represented with black lines, 0.0001, 0.001, and 0.01% (w/v)
curcumin is represented in yellow, orange, and red lines
respectively.
(TIF)
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malized median survival time as a function of curcumin
concentration. The data on the y-axis was calculated from the
median survival time for each genotype without treatment
(T1/2 (0%)) versus treatment with the respective curcumin
concentration (T1/2 (x%)). Control flies (black), Ab1–40 expressing
flies (cyan), single insert Ab1–42 expressing flies (blue), double insert
Ab1–42 expressing flies (green), Ab1–42 E22G expressing flies (red),
and Tau expressing flies (magenta).
(TIF)
Figure S9 Histological sections of Drosophila eyes co-
stained with p-FTAA and antibody. Micrographs of 20 day
old GMR-Gal4/UAS- Drosophila eyes taken with 1006 objective
showing fluorescence from cell nuclei by DAPI (blue), amyloid
aggregates by p-FTAA (green) and Ab or Tau by aAb or aTau-
antibody (red). (A) Untreated and (B) curcumin treated control flies
shown in exhibited no antibody or LCO binding species within the
eye. Background staining was seen in the retina. (C) Ab1–40
expressing flies and the same transgene treated with curcumin (D)
showed small amyloid staining of LCO and antibody species
surrounding the nuclei. (E) Single insert Ab1–42 expressing flies
showed strong amyloid staining with LCO, predominantly
surrounding the nuclei. The aggregates propagated along the
ommatidia. (F) The same level and location of amyloid deposits
were observed in the curcumin treated single insert Ab1–42
expressing flies. (G) Double insert Ab1–42 expressing flies showed
extensive amyloid staining including several long extended fibrillar
aggregates. DAPI staining from regions with extensive LCO-
positive amyloid structures was markedly decreased. (H) The same
level and location of amyloid deposits were observed in the
curcumintreateddoubleinsertAb1–42expressingflies.(I)Ab1–42 E22G
expressing flies showed spot-like staining from both LCO and the
Ab antibody, but exhibited a weaker LCO staining than that
displayed for wild type single and double insert Ab1–42 expressing
flies. Some irregular nuclei were visible from the DAPI staining.
(J) The same staining pattern was reveled for the curcumin
treated Ab1–42 E22G expressing flies. (K) Tau expressing flies, and
(L) the same transgene treated with curcumin, displayed extensive
LCO and antibody-binding aggregates. The aggregates were
mostly found in regions were no or few nuclei were visible. Scale
bars represent 50 mm. Arrows indicate small aggregates and filled
arrowheads indicate long extended fibrillar structures. Unfilled
arrow head indicates large aggregates in areas with massive tissue
degradation.
(TIF)
Table S1 Median survival time (T1/2) in days for C155-
Gal4 crossings of genotypes with altered curcumin
concentration.
(DOCX)
Table S2 Median time of successful climbing (T1/2
climbing) in days for C155-Gal4 crossings of genotypes
with altered curcumin concentration.
(DOCX)
Table S3 Mean concentration (pg) Ab/(mg) total protein
± SEM for soluble and insoluble samples per fly.
(DOCX)
Table S4 Mean concentration (pg) Ab/(mg) total protein
± SEM for soluble and insoluble samples per fly.
(DOCX)
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